• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tirabrutinib for CNS relapsed primary vitreoretinal lymphoma.

作者信息

Yoshida Nao, Ureshino Hiroshi, Hiyama Tomona, Harada Yosuke, Nakatani Suzuka, Chishaki Ren, Edahiro Taro, Yoshida Tetsumi, Shindo Takero, Ichinohe Tatsuo

机构信息

Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8553, Japan.

Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.

出版信息

Ann Hematol. 2025 Mar;104(3):2073-2074. doi: 10.1007/s00277-025-06284-3. Epub 2025 Mar 4.

DOI:10.1007/s00277-025-06284-3
PMID:40032699
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12031790/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e2/12031790/722b5690a8be/277_2025_6284_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e2/12031790/722b5690a8be/277_2025_6284_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e2/12031790/722b5690a8be/277_2025_6284_Fig1_HTML.jpg

相似文献

1
Tirabrutinib for CNS relapsed primary vitreoretinal lymphoma.替拉鲁替尼用于中枢神经系统复发的原发性玻璃体视网膜淋巴瘤
Ann Hematol. 2025 Mar;104(3):2073-2074. doi: 10.1007/s00277-025-06284-3. Epub 2025 Mar 4.
2
Refractory Primary Vitreoretinal Lymphoma Involving the Spinal Cord with a Temporary Complete Response to Tirabrutinib.难治性原发性玻璃体内视网膜淋巴瘤累及脊髓，替拉鲁替尼治疗暂时完全缓解。
Intern Med. 2023 Feb 1;62(3):459-463. doi: 10.2169/internalmedicine.9591-22. Epub 2022 Jul 5.
3
Successful bridging therapy with tirabrutinib before ASCT for relapsed primary DLBCL of the CNS complicated with PBC, cirrhosis, and pancytopenia.在进行自体干细胞移植（ASCT）之前，使用替拉布替尼进行成功的桥接治疗，用于复发性中枢神经系统原发性弥漫性大B细胞淋巴瘤（DLBCL）合并原发性胆汁性胆管炎（PBC）、肝硬化和全血细胞减少症。
Leuk Res Rep. 2022 May 30;17:100331. doi: 10.1016/j.lrr.2022.100331. eCollection 2022.
4
Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma.替拉鲁替尼治疗复发/难治性原发性中枢神经系统淋巴瘤疗效的组织学验证
Exp Hematol Oncol. 2021 Apr 26;10(1):29. doi: 10.1186/s40164-021-00222-5.
5
Efficacy and safety of tirabrutinib monotherapy in relapsed or refractory B-cell lymphomas/leukemia: a meta-analysis.替拉布替尼单药治疗复发或难治性B细胞淋巴瘤/白血病的疗效和安全性：一项荟萃分析。
Front Pharmacol. 2025 Apr 1;16:1559056. doi: 10.3389/fphar.2025.1559056. eCollection 2025.
6
Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib.来自替拉布替尼I/II期研究的复发或难治性原发性中枢神经系统淋巴瘤患者的卡诺夫斯基体能状态和生活质量
Neurooncol Adv. 2023 Sep 14;5(1):vdad109. doi: 10.1093/noajnl/vdad109. eCollection 2023 Jan-Dec.
7
Diagnosis and management of vitreoretinal lymphoma: present and future treatment perspectives.玻璃体内视网膜淋巴瘤的诊断与治疗：现状与未来治疗展望。
Jpn J Ophthalmol. 2023 Jul;67(4):363-381. doi: 10.1007/s10384-023-00997-6. Epub 2023 May 20.
8
Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.替拉鲁替尼（第二代布鲁顿酪氨酸激酶抑制剂）治疗复发/难治性原发性中枢神经系统淋巴瘤的 I/II 期研究。
Neuro Oncol. 2021 Jan 30;23(1):122-133. doi: 10.1093/neuonc/noaa145.
9
Experience With Tirabrutinib in the Treatment of Primary Central Nervous System Lymphoma that Is Difficult to Treat With Standard Treatment.治疗标准治疗难治性原发性中枢神经系统淋巴瘤的替拉鲁替尼治疗经验。
Anticancer Res. 2022 Aug;42(8):4173-4178. doi: 10.21873/anticanres.15917.
10
Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.替拉鲁替尼治疗复发或难治性原发性中枢神经系统淋巴瘤患者的1/2期研究的三年随访分析
Neurooncol Adv. 2024 Apr 22;6(1):vdae037. doi: 10.1093/noajnl/vdae037. eCollection 2024 Jan-Dec.

本文引用的文献

1
Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.替拉鲁替尼治疗复发或难治性原发性中枢神经系统淋巴瘤患者的1/2期研究的三年随访分析
Neurooncol Adv. 2024 Apr 22;6(1):vdae037. doi: 10.1093/noajnl/vdae037. eCollection 2024 Jan-Dec.
2
Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies.替拉鲁替尼的长期安全性特征：在复发或难治性 B 细胞恶性肿瘤患者中进行的一项日本 I 期研究的最终结果。
Int J Hematol. 2023 Apr;117(4):553-562. doi: 10.1007/s12185-022-03514-6. Epub 2022 Dec 28.
3
Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study.
原发性脑淋巴瘤的孤立性眼内复发：一项LOC网络研究。
Hematol Oncol. 2022 Dec;40(5):976-986. doi: 10.1002/hon.3044. Epub 2022 Jul 14.
4
Primary vitreoretinal lymphoma: a diagnostic and management challenge.原发性玻璃体视网膜淋巴瘤：诊断和治疗的挑战。
Blood. 2021 Oct 28;138(17):1519-1534. doi: 10.1182/blood.2020008235.
5
Primary vitreoretinal lymphomas display a remarkably restricted immunoglobulin gene repertoire.原发性玻璃体视网膜淋巴瘤表现出显著受限的免疫球蛋白基因库。
Blood Adv. 2020 Apr 14;4(7):1357-1366. doi: 10.1182/bloodadvances.2019000980.
6
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.伊布替尼单药治疗复发或难治性原发性中枢神经系统淋巴瘤和原发性玻璃体视网膜淋巴瘤：淋巴瘤研究协会 (LYSA) 和法国眼脑淋巴瘤 (LOC) 网络进行的 II 期“概念验证”iLOC 研究的最终分析。
Eur J Cancer. 2019 Aug;117:121-130. doi: 10.1016/j.ejca.2019.05.024. Epub 2019 Jul 3.
7
Ibrutinib brain distribution: a preclinical study.依鲁替尼脑内分布：一项临床前研究。
Cancer Chemother Pharmacol. 2018 Apr;81(4):783-789. doi: 10.1007/s00280-018-3546-3. Epub 2018 Feb 23.
8
Combined intravitreal methotrexate and immunochemotherapy followed by reduced-dose whole-brain radiotherapy for newly diagnosed B-cell primary intraocular lymphoma.玻璃体腔注射甲氨蝶呤联合免疫化疗，随后进行低剂量全脑放疗用于新诊断的B细胞原发性眼内淋巴瘤。
Br J Haematol. 2017 Oct;179(2):246-255. doi: 10.1111/bjh.14848. Epub 2017 Jul 12.
9
Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.原发性中枢神经系统淋巴瘤首次复发/进展：来自法国LOC网络的256例患者的特征、治疗及预后
Neuro Oncol. 2016 Sep;18(9):1297-303. doi: 10.1093/neuonc/now033. Epub 2016 Mar 6.
10
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.弥漫性大 B 细胞淋巴瘤中慢性活性 B 细胞受体信号转导。
Nature. 2010 Jan 7;463(7277):88-92. doi: 10.1038/nature08638.